loading page

Mitral Valve Surgery for Non-ischemic Functional Mitral Regurgitation In Patients With Severe Left Ventricular Dysfunction and Five Years Follow-up
  • +2
  • Jun Pan,
  • Can Xu,
  • Zhenjun Xu,
  • Zirun Lu,
  • wang dongjin
Jun Pan
Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital
Author Profile
Can Xu
Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital
Author Profile
Zhenjun Xu
Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital
Author Profile
Zirun Lu
Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital
Author Profile
wang dongjin
The Affiliated Drum Tower Hospital of Nanjing University Medical School
Author Profile

Abstract

Background: To assess the effects of mitral valve (MV) replacement for functional mitral regurgitation (FMR) in patients with severe left ventricular (LV) dysfunction. Methods: 48 patients with secondary non-ischemic severe mitral regurgitation (MR) and left ventricle eject fraction (LVEF) less than 35% were underwent MV replacement. All surgeries were finished by one surgical team from January 2010 to December 2015. Twenty-three patients were females and the mean age was 60.21 ± 10.69 years (range, 29~75 years). The preoperative cardiac function classification was Ⅲ~Ⅳ (NYHA) in 40 patients. The mean follow-up time was five years. Results: Three patients (6.3%) died in hospital: 2 from low output syndrome and 1 from multi-organ failure induced by pulmonary infection. The mean postoperative intensive care unit (ICU) stay time was 4 days. The mean cardiopulmonary bypass time was 131.50 ± 3.92 min, and the mean aortic cross-clamping time was 85.39 ± 24.16 min. The left atrium diameter and the systolic pulmonary artery pressure (PAP) decreased significantly after surgery. The survival rates at 1 and 5 years were 83.3% and 54.6%, and 29 patients (60.4 %) were in NYHA class Ⅰ/Ⅱ during the follow-up time. Conclusions: Mitral valve replacement maybe offers symptomatic improvement and mid-term survival benefit for non-ischemic FMR in some patients with severe LV dysfunction.